Astrocyte Marker GFAP Identifies Elevated Cognitive Decline Risk Across Alzheimer Continuum
Elevated plasma GFAP combined with p-tau217 identifies individuals facing faster cognitive decline and greater risk of clinical worsening across the ...
Elevated plasma GFAP combined with p-tau217 identifies individuals facing faster cognitive decline and greater risk of clinical worsening across the ...
Automated blood tests measuring phosphorylated tau 217 demonstrated diagnostic accuracy comparable to authorized cerebrospinal fluid tests for identifying Alzheimer’s disease ...
A prospective multicenter study across seven memory clinics in Spain demonstrated that automated plasma p-tau217 testing accurately identifies brain amyloidosis ...
A cross-sectional cohort study reveals that Alzheimer's disease co-pathology in dementia with Lewy bodies is linked to stage-dependent visual impairments ...
A post hoc analysis of the TRAILBLAZER-ALZ 2 trial found that lower baseline amyloid, older age, fewer APOE ε4 alleles ...
A real-world study of 1,368 patients across 24 centers shows plasma p-tau217 distributions vary by clinical category, age and kidney ...
A large autopsy-validated study shows that cerebrospinal fluid and plasma Alzheimer's biomarkers become abnormal in a defined sequence as amyloid-beta ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine